Screening the receptorome for plant-based psychoactive compounds.
Kerry Ann O'Connor, Bryan L. Roth
Life Sciences December 22, 2005 DOI: 10.1016/j.lfs.2005.09.002 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Methodology description Peer reviewed |
|---|---|
| Keywords | Plant compounds Natural compounds Plant-derived substances Phytochemicals Botanical compounds Receptor screening High-throughput screening Molecular target identification Ligand screening Receptor interaction Drug discovery Therapeutic discovery Bioactive compound discovery Medicinal chemistry Pharmaceutical research Neuropharmacology Psychoactive compounds Brain research Neurobiology Psychopharmacology |
| Citations | 22 |
| Key points | A high-throughput screening system was developed to identify molecular targets of psychoactive plant compounds, demonstrated with Salvia divinorum and Banisteriopsis caapi. |
Abstract
Throughout time, humans have used psychoactive plants and plant-derived products for spiritual, therapeutic and recreational purposes. Furthermore, the investigation of psychoactive plants such as Cannabis sativa (marijuana), Nicotiana tabacum (tobacco) and analogues of psychoactive plant derivatives such as lysergic acid diethylamide (LSD) have provided insight into our understanding of neurochemical processes and diseases of the CNS. Currently, many of these compounds are being used to treat a variety of diseases, such as depression and anxiety in the case of Piper methysticum Kava Kava (Martin et al., 2002; Singh and Singh, 2002). G-protein coupled receptors (GPCRs) are the most common molecular target for both psychoactive drugs and pharmaceuticals. The "receptorome" (that portion of the genome encoding ligand reception) encompasses more than 8% of the human genome (Roth et al., 2004) and as such provides a large number of possible targets for psychoactive drug interactions. A systematic, comprehensive study is necessary to identify novel active psychoactive plant-based compounds and the molecular targets of known compounds. Herein we describe the development of a high throughput system (HTS) to screen psychoactive compounds against the receptorome and present two examples (Salvia divinorum, the "magic mint" hallucinogen and Banisteriopsis caapi, the main component of Ayahuasca, a psychoactive beverage) where HTS enabled the identification of the molecular target of each compound.
Citations in the library
Cited by 7
- Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. British Journal of Pharmacology November 1, 2008
- Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. Planta Medica August 1, 2007
- The globalization of traditional medicine in northern peru: from shamanism to molecules. Evidence-based Complementary and Alternative Medicine December 28, 2013
- Ayahuasca: Uses, Phytochemical and Biological Activities Natural Products and Bioprospecting May 27, 2019
- Psychoactive natural products: overview of recent developments. Annali dell'Istituto superiore di sanita 2014
and 2 more in the library
Cites 11
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics March 1, 2004
- Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint, Salvia divinorum The Journal of Organic Chemistry November 1, 1984
- Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. TIPS - Trends in Pharmacological Sciences March 1, 2003
- Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine Journal of Psychoactive Drugs April 1, 1999
and 6 more in the library